Investors sold shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on strength during trading on Monday. $74.81 million flowed into the stock on the tick-up and $95.84 million flowed out of the stock on the tick-down, for a money net flow of $21.03 million out of the stock. Of all stocks tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $7.73 for the day and closed at $381.54

Several analysts have commented on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $444.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 19th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $436.00 to $415.00 in a research note on Friday, April 8th. Wells Fargo & Co. downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 20th. Brean Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 12th. Finally, Cowen and Company reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, April 17th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $508.32.

The stock has a market cap of $39.79 billion and a P/E ratio of 60.49. The company’s 50 day moving average is $369.33 and its 200 day moving average is $395.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $2.57 EPS for the quarter, missing the consensus estimate of $2.58 by $0.01. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.18 billion. The firm’s revenue for the quarter was up 38.0% compared to the same quarter last year. During the same period last year, the firm earned $2.88 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals Inc. will post $10.80 earnings per share for the current fiscal year.

In other news, EVP Plew Daniel P. Van sold 4,413 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $385.77, for a total transaction of $1,702,403.01. Following the completion of the sale, the executive vice president now directly owns 11,381 shares in the company, valued at $4,390,448.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Sanofi bought 64,731 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The shares were acquired at an average price of $363.86 per share, with a total value of $23,553,021.66. The disclosure for this purchase can be found here.

Several hedge funds have added to or reduced their stakes in the company. Tredje AP fonden increased its stake in Regeneron Pharmaceuticals by 398.7% in the fourth quarter. Tredje AP fonden now owns 23,463 shares of the biopharmaceutical company’s stock valued at $12,737,000 after buying an additional 18,758 shares during the period. Sawtooth Asset Management Inc. increased its stake in Regeneron Pharmaceuticals by 6,115.5% in the fourth quarter. Sawtooth Asset Management Inc. now owns 3,605 shares of the biopharmaceutical company’s stock valued at $1,957,000 after buying an additional 3,547 shares during the last quarter. Financial Counselors Inc. increased its stake in Regeneron Pharmaceuticals by 5.3% in the fourth quarter. Financial Counselors Inc. now owns 1,846 shares of the biopharmaceutical company’s stock valued at $1,002,000 after buying an additional 93 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,657 shares of the biopharmaceutical company’s stock valued at $4,700,000 after buying an additional 93 shares during the last quarter. Finally, Gulf International Bank UK Ltd increased its stake in Regeneron Pharmaceuticals by 1.8% in the fourth quarter. Gulf International Bank UK Ltd now owns 22,956 shares of the biopharmaceutical company’s stock valued at $12,462,000 after buying an additional 400 shares during the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.